UOC
STLNW

UBS O'Connor’s Starling Oncology Warrant STLNW Stock Holding History

UBS O'Connor’s Portfolio STLNW Stock Details STLNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-372,284
Closed -$577K – 1013
2021
Q3 		$577K Hold
372,284
– – ﹤0.01% 639
2021
Q2 		$655K Hold
372,284
– – 0.01% 594
2021
Q1 		$531K Buy
+372,284
New +$690K 0.01% 599

Other funds holding STLNW

LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
DCM
Difesa Capital Management New York $38.1M AUM 39.86% 1-Year Est. Return
USPCM
Union Square Park Capital Management New York $278M AUM 50.01% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $62.7B AUM 29.77% 1-Year Est. Return

UBS O'Connor's STLNW Position: Q4 2021 in Review

UBS O'Connor sold out of Starling Oncology Warrant (STLNW) in Q4 2021, closing a stake of 372,284 shares — an estimated $577K sold.

UBS O'Connor first reported a position in STLNW in Q1 2021 and held it in 3 quarters. The position peaked at $655K in Q2 2021. 20 funds tracked by Wall St. Rank hold STLNW as of Q4 2021.

  • UBS O'Connor reported no remaining Starling Oncology Warrant position as of Q4 2021 after selling out during the quarter.
  • UBS O'Connor sold 372,284 Starling Oncology Warrant shares in Q4 2021, an estimated $577K.
  • UBS O'Connor first reported a position in Starling Oncology Warrant in Q1 2021 and held it in 3 quarters.
  • UBS O'Connor's Starling Oncology Warrant position peaked at $655K in Q2 2021.
  • 20 funds tracked by Wall St. Rank held Starling Oncology Warrant as of Q4 2021.

Based on UBS O'Connor's 13F filing for Q4 2021, filed 14 Feb 2022.